Buy Taufon eye drops 4%, 10 ml
  • Buy Taufon eye drops 4%, 10 ml


Moscow Endocrine Plant
895 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Eye drops Taufon - anti-cataract agent, has a retinoprotective (with subconjunctival administration) and metabolic effect.

Taurine is a sulfur-containing amino acid that is formed in the body during the conversion of cysteine. Stimulates the processes of reparation and regeneration in case of diseases of a dystrophic nature and diseases accompanied by a sharp disturbance of the metabolism of eye tissues.

Contributes to the normalization of cell membrane functions, activation of energy and metabolic processes, preservation of the electrolyte composition of the cytoplasm due to the accumulation of K+ and Ca2+, improve the conditions of the nerve impulse.


  • Corneal dystrophy;
  • cataract (senile, diabetic, traumatic, radiation);
  • corneal injury (as a stimulator of reparative processes);
  • dystrophic lesions of the retina, including hereditary tapethorethinal abiotrophy.


1 ml of solution contains:

Active substances: Taurine - 40 mg.

Excipients: methyl hydroxybenzoate 1 mg, sodium hydroxide solution 1 M to pH 5.0 - 6.5, water d / and up to 1 ml.

Taurine is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Taufon Moscow Endocrine Plant Russia eye drops
Taurine SOLOpharm Grotex Ltd Russia eye drops
CardioActive Evalar Russia pills
Taurine Diapharm Russia eye drops
Taurine PFK Obnovlenie Russia eye drops
Taurine Synthesis AKOMP Russia eye drops
Dibicor Piq-Pharma Russia pills

No customer reviews for the moment.

Write your review

Write your review


Dosage and Administration

With cataract prescribed in the form of instillation 1-2 drops 2-4 times a day for 3 months. The course is repeated at monthly intervals.

For injuries and dystrophic diseases of the cornea used in the same doses for 1 month.

For the treatment of tapethoretinal abiotrophy and other degenerative diseases of the retina, with penetrating wounds, the cornea is injected under the conjunctiva with 0.3 ml of a 4% solution once a day for 10 days. The course of treatment is repeated after 6-8 months.

Adverse reactions

Allergic reactions.


Individual hypersensitivity to taurine, children under 18 years of age.

Drug interactions

In patients with glaucoma (open angle), a significant increase in the hypotensive effect of β-blockers (timolol and butylaminohydroxy-propoxyphenoxymethyl methyloxadiazole) was observed in the case of joint use with Tauphone.

Strengthening the effect is achieved by increasing the coefficient of lightness outflow and reduce the production of aqueous humor.

Pregnancy and Lactation

Use of the drug during pregnancy and lactation is possible only after the risk / benefit ratio (efficacy and safety have not been established).

  • Active ingredient: Taurine

Studies and clinical trials of Taurine (Click to expand)

  1. Taurine in rat posterior pituitary: Localization in astrocytes and selective release by hypoosmotic stimulation
  2. Erythropoietin stimulates tyrosine phosphorylation and taurine transport in skate erythrocytes
  3. Taurine attenuates recombinant interleukin-2-activated, lymphocyte-mediated endothelial cell injury
  4. Regeneration and myogenic cell proliferation correlate with taurine levels in dystrophin- and MyoD-Deficient muscles
  5. Relation of taurine transport and brain edema in rats with simple hyperammonemia or liver failure
  6. Effects of phenylsuccinate on potassium-stimulated taurine release in cultured neurons and astrocytes and in rat hippocampus in vivo
  7. Ammonia-induced taurine release from cultured rabbit müller cells is an osmoresistant process mediated by intracellular accumulation of cyclic AMP
  8. Taurine might be acting as a trophic factor in the retina by modulating phosphorylation of cellular proteins
  9. Activation and inactivation of taurine efflux in hyposmotic and isosmotic swelling in cortical astrocytes: Role of ionic strength and cell volume decrease
  10. Volume-activated taurine permeability in cells of the human erythroleukemic cell line K562
  11. Inhibition of Na+, K+-ATPase activates swelling-induced taurine efflux in a human neuroblastoma cell line
  12. Increased potassium, chloride, and taurine conductances in astrocytes during hypoosmotic swelling
  13. Thiols and polyamines in the cytoprotective effect of taurine on carbon tetrachloride-induced hepatotoxicity
  14. The influence of cations on the dissociation behaviour of copolymers of propene and maleic acid and their modified products with taurine in salt-free solution
  15. Lower CSF Taurine Levels in Male Pathological Gamblers than in Healthy Controls
  16. The synthesis of taurine-conjugated bile acids and bile acid sulfates labeled with 14C or 3H in the taurine moiety
  17. Homeostasis of taurine and glutamate plasma levels after acute and chronic ethanol administration in man
  18. A localized double-quantum filter for in vivo detection of taurine
  19. Determination of taurine in plasma by capillary zone electrophoresis following derivatisation with fluorescamine
  20. High-pressure Raman study of taurine crystal
  21. Chitosan film enriched with an antioxidant agent, taurine, in fenestration defects
  22. Taurine chloramine inhibition of cell proliferation and cytokine production by rheumatoid arthritis fibroblast-like synoviocytes
  23. The mechanism of taurine chloramine inhibition of cytokine (interleukin-6, interleukin-8) production by rheumatoid arthritis fibroblast-like synoviocytes
  24. Kinetics of the reaction of CO2 with aqueous potassium salt of taurine and glycine

Customers who bought this product also bought:

8 other products in the same category: